B. Tsuji

发表

Two Mechanisms of Killing of Pseudomonas aeruginosa by Tobramycin Assessed at Multiple Inocula via Mechanism-Based Modeling

Neang S. Ly, Lisandra L. Martin, A. Oliver, 2015, Antimicrobial Agents and Chemotherapy.

Pharmacokinetic/Pharmacodynamic Investigation of Colistin against Pseudomonas aeruginosa Using an In Vitro Model

Brian T. Tsuji, Phillip J. Bergen, J. Li, 2010, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?

Brian T. Tsuji, Phillip J. Bergen, R. Nation, 2016, International journal of antimicrobial agents.

ColistinDose, a Mobile App for Determining Intravenous Dosage Regimens of Colistimethate in Critically Ill Adult Patients: Clinician-Centered Design and Development Study (Preprint)

Varun S. Sharma, K. Kaye, Phillip J. Bergen, 2020 .

Front-Loaded Linezolid Regimens Result in Increased Killing and Suppression of the Accessory Gene Regulator System of Staphylococcus aureus

Brian T. Tsuji, D. Brazeau, D. Hanna, 2012, Antimicrobial Agents and Chemotherapy.

Comparable Efficacy and Better Safety of Double β-Lactam Combination Therapy versus β‑Lactam plus Aminoglycoside in Gram-Negative Bacteria in Randomized, Controlled Trials

Brian T. Tsuji, R. Bonomo, G. Drusano, 2019, Antimicrobial Agents and Chemotherapy.

Short-Course Gentamicin in Combination with Daptomycin or Vancomycin against Staphylococcus aureus in an In Vitro Pharmacodynamic Model with Simulated Endocardial Vegetations

Brian T. Tsuji, M. Rybak, B. Tsuji, 2005, Antimicrobial Agents and Chemotherapy.

Linezolid‐Associated Peripheral and Optic Neuropathy, Lactic Acidosis, and Serotonin Syndrome

Brian T. Tsuji, V. Yu, B. Tsuji, 2007, Pharmacotherapy.

Pharmacodynamic Issues in Antibiotic Combinations

Brian T. Tsuji, B. Tsuji, Zackery P. Bulman, 2016 .

Relevance of pharmacokinetic and pharmacodynamic modeling to clinical care of critically ill patients.

M. Neely, C. Landersdorfer, J. Bulitta, 2011, Current pharmaceutical biotechnology.

Synergistic Killing of Multidrug-Resistant Pseudomonas aeruginosa at Multiple Inocula by Colistin Combined with Doripenem in an In Vitro Pharmacokinetic/Pharmacodynamic Model

Brian T. Tsuji, D. Paterson, Phillip J. Bergen, 2011, Antimicrobial Agents and Chemotherapy.

New Dosing Strategies for an Old Antibiotic: Pharmacodynamics of Front-Loaded Regimens of Colistin at Simulated Pharmacokinetics in Patients with Kidney or Liver Disease

Neang S. Ly, J. Li, R. Nation, 2013, Antimicrobial Agents and Chemotherapy.

Clinically Relevant Plasma Concentrations of Colistin in Combination with Imipenem Enhance Pharmacodynamic Activity against Multidrug-Resistant Pseudomonas aeruginosa at Multiple Inocula

Brian T. Tsuji, D. Paterson, Phillip J. Bergen, 2011, Antimicrobial Agents and Chemotherapy.

Community- and health care-associated methicillin-resistant Staphylococcus aureus: a comparison of molecular epidemiology and antimicrobial activities of various agents.

Brian T. Tsuji, G. Kaatz, M. Amjad, 2007, Diagnostic microbiology and infectious disease.

Fluoroquinolone Resistance in Streptococcus pneumoniae: Area Under the Concentration-Time Curve/MIC Ratio and Resistance Development with Gatifloxacin, Gemifloxacin, Levofloxacin, and Moxifloxacin

Brian T. Tsuji, G. Kaatz, M. Rybak, 2007, Antimicrobial Agents and Chemotherapy.

Polymyxin Triple Combinations against Polymyxin-Resistant, Multidrug-Resistant, KPC-Producing Klebsiella pneumoniae

Brian T. Tsuji, Su Mon Aye, J. Li, 2020, Antimicrobial Agents and Chemotherapy.

Impact of Staphylococcus aureus accessory gene regulator (agr) system on linezolid efficacy by profiling pharmacodynamics and RNAIII expression

R. Soon, A. Forrest, B. Tsuji, 2017, The Journal of Antibiotics.

A combination of ceftaroline and daptomycin has synergistic and bactericidal activity in vitro against daptomycin nonsusceptible methicillin-resistant Staphylococcus aureus (MRSA)

Brian T. Tsuji, A. Lesse, G. Parameswaran, 2017, Infectious diseases.

Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin

Neang S. Ly, J. Bulitta, B. Tsuji, 2017, Antimicrobial Agents and Chemotherapy.

Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria

Brian T. Tsuji, C. Landersdorfer, Phillip J. Bergen, 2015, Infectious Diseases and Therapy.

The Combination of Colistin and Doripenem Is Synergistic against Klebsiella pneumoniae at Multiple Inocula and Suppresses Colistin Resistance in an In Vitro Pharmacokinetic/Pharmacodynamic Model

D. Paterson, Phillip J. Bergen, J. Li, 2012, Antimicrobial Agents and Chemotherapy.

Effect of Fluoroquinolones and Macrolides on Eradication and Resistance of Haemophilus influenzae in Chronic Obstructive Pulmonary Disease

Y. Kong, J. Gent, T. Murphy, 2016, Antimicrobial Agents and Chemotherapy.

High-intensity meropenem combinations with polymyxin B: new strategies to overcome carbapenem resistance in Acinetobacter baumannii

C. Landersdorfer, B. Shin, J. Li, 2017, The Journal of antimicrobial chemotherapy.

Paradoxical Effect of Polymyxin B: High Drug Exposure Amplifies Resistance in Acinetobacter baumannii

Brian T. Tsuji, C. Landersdorfer, J. Li, 2016, Antimicrobial Agents and Chemotherapy.

Colistin and doripenem combinations against Pseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance.

Neang S. Ly, C. Landersdorfer, Phillip J. Bergen, 2015, The Journal of antimicrobial chemotherapy.

Pharmacodynamics of early, high-dose linezolid against vancomycin-resistant enterococci with elevated MICs and pre-existing genetic mutations.

Laura A. Skerlos, D. Hanna, J. Bulitta, 2012, The Journal of antimicrobial chemotherapy.

Loss of vancomycin bactericidal activity against accessory gene regulator (agr) dysfunctional Staphylococcus aureus under conditions of high bacterial density.

A. Lesse, B. Tsuji, G. Sakoulas, 2009, Diagnostic microbiology and infectious disease.

Pharmacodynamics of Vancomycin at Simulated Epithelial Lining Fluid Concentrations against Methicillin-Resistant Staphylococcus aureus (MRSA): Implications for Dosing in MRSA Pneumonia

A. Lesse, J. Bulitta, A. Forrest, 2009, Antimicrobial Agents and Chemotherapy.

Alterations of Metabolic and Lipid Profiles in Polymyxin-Resistant Pseudomonas aeruginosa

Brian T. Tsuji, Alina D. Gutu, J. Li, 2018, Antimicrobial Agents and Chemotherapy.

Shifting Gears: The Future of Polymyxin Antibiotics

Brian T. Tsuji, K. Kaye, B. Tsuji, 2019, Antibiotics.

Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam–β-Lactamase Inhibitor Combinations

R. Soon, A. Forrest, B. Tsuji, 2016, Antimicrobial Agents and Chemotherapy.

Shape does matter: short high-concentration exposure minimizes resistance emergence for fluoroquinolones in Pseudomonas aeruginosa.

C. Landersdorfer, F. Sörgel, R. Nation, 2015, The Journal of antimicrobial chemotherapy.

A Comparative Review of the Lipoglycopeptides: Oritavancin, Dalbavancin, and Telavancin

B. Tsuji, Michael T. Guskey, 2010, Pharmacotherapy.

Polymyxin Combinations: Pharmacokinetics and Pharmacodynamics for Rationale Use

Brian T. Tsuji, C. Landersdorfer, Phillip J. Bergen, 2015, Pharmacotherapy.

Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii: pharmacodynamics of new dosing strategies.

Neang S. Ly, C. Landersdorfer, J. Li, 2016, The Journal of antimicrobial chemotherapy.

Optimization of Polymyxin B in Combination with Doripenem To Combat Mutator Pseudomonas aeruginosa

Neang S. Ly, Jian Li, M. Sutton, 2016, Antimicrobial Agents and Chemotherapy.

Synergistic Activity of Colistin and Rifampin Combination against Multidrug-Resistant Acinetobacter baumannii in an In Vitro Pharmacokinetic/Pharmacodynamic Model

Phillip J. Bergen, J. Li, R. Nation, 2013, Antimicrobial Agents and Chemotherapy.

Resurgence of Colistin: A Review of Resistance, Toxicity, Pharmacodynamics, and Dosing

Neang S. Ly, Brian T. Tsuji, J. Bulitta, 2010, Pharmacotherapy.

Pharmacodynamics of colistin and fosfomycin: a ‘treasure trove’ combination combats KPC-producing Klebsiella pneumoniae

Brian T. Tsuji, Phillip J. Bergen, J. Li, 2017, The Journal of antimicrobial chemotherapy.

In Pursuit of the triple Crown: mechanism-based pharmacodynamic modeling for the optimization of 3-drug combinations against KPC-Producing Klebsiella pneumoniae.

R. Nation, Jian Li, J. Bulitta, 2020, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activity

Brian T. Tsuji, K. Kaye, R. Nation, 2017, The Journal of antimicrobial chemotherapy.

Integrated metabolomic and transcriptomic analyses of the synergistic effect of polymyxin–rifampicin combination against Pseudomonas aeruginosa

Brian T. Tsuji, Jian Li, J. Li, 2022, Journal of Biomedical Science.

Sequential Evolution of Vancomycin-Intermediate Resistance Alters Virulence in Staphylococcus aureus: Pharmacokinetic/Pharmacodynamic Targets for Vancomycin Exposure

S. Gill, D. Brazeau, M. Rybak, 2015, Antimicrobial Agents and Chemotherapy.

Successful cure of daptomycin-non-susceptible, vancomycin-intermediate Staphylococcus aureus prosthetic aortic valve endocarditis directed by synergistic in vitro time-kill study

K. Mergenhagen, B. Tsuji, C. Berenson, 2019, Infectious diseases.

Ampicillin Enhances Daptomycin- and Cationic Host Defense Peptide-Mediated Killing of Ampicillin- and Vancomycin-Resistant Enterococcus faecium

Brian T. Tsuji, V. Nizet, J. Pogliano, 2011, Antimicrobial Agents and Chemotherapy.

Comparative pharmacodynamics of four different carbapenems in combination with polymyxin B against carbapenem-resistant Acinetobacter baumannii.

C. Landersdorfer, J. Li, R. Nation, 2016, International journal of antimicrobial agents.

Combinatorial pharmacodynamics of polymyxin B and tigecycline against heteroresistant Acinetobacter baumannii.

Neang S. Ly, J. Li, R. Nation, 2016, International journal of antimicrobial agents.

The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections

Brian T. Tsuji, V. Tam, M. Bassetti, 2017, Intensive Care Medicine.

Resistance suppression by high-intensity, short-duration aminoglycoside exposure against hypermutable and non-hypermutable Pseudomonas aeruginosa.

A. Oliver, C. Landersdorfer, C. Rayner, 2016, The Journal of antimicrobial chemotherapy.

Evolution of Staphylococcus aureus under Vancomycin Selective Pressure: the Role of the Small-Colony Variant Phenotype

Brian T. Tsuji, B. Tsuji, C. von Eiff, 2014, Antimicrobial Agents and Chemotherapy.

Impact of accessory gene regulator (agr) dysfunction on vancomycin pharmacodynamics among Canadian community and health-care associated methicillin-resistant Staphylococcus aureus

Brian T. Tsuji, L. Dresser, A. Simor, 2011, Annals of Clinical Microbiology and Antimicrobials.

Synergistic combinations of polymyxins.

Brian T. Tsuji, R. Nation, B. Tsuji, 2016, International journal of antimicrobial agents.

Characterization of heterogeneous vancomycin-intermediate resistance, MIC and accessory gene regulator (agr) dysfunction among clinical bloodstream isolates of staphyloccocus aureus

Brian T. Tsuji, A. Lesse, B. Tsuji, 2011, BMC infectious diseases.

Concentration‐dependent plasma protein binding: Expect the unexpected

Brian T. Tsuji, R. Nation, U. Theuretzbacher, 2018, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Evaluation of Accessory Gene Regulator (agr) Group and Function in the Proclivity towards Vancomycin Intermediate Resistance in Staphylococcus aureus

Brian T. Tsuji, M. Rybak, B. Tsuji, 2006, Antimicrobial Agents and Chemotherapy.

Polymyxin Combinations against Pseudomonas aeruginosa : Profiling the Time-Course of Synergistic Killing and Prevention of Resistance

Neang S. Ly, C. Landersdorfer, R. Nation, 2015 .

Etest synergy testing of clinical isolates of Staphylococcus aureus demonstrating heterogeneous resistance to vancomycin.

Brian T. Tsuji, M. Rybak, B. Tsuji, 2006, Diagnostic microbiology and infectious disease.

Rational Combinations of Polymyxins with Other Antibiotics.

Brian T. Tsuji, B. Tsuji, Raymond Cha, 2019, Advances in experimental medicine and biology.

Impact of Two-Component Regulatory Systems PhoP-PhoQ and PmrA-PmrB on Colistin Pharmacodynamics in Pseudomonas aeruginosa

Neang S. Ly, J. Bulitta, B. Tsuji, 2012, Antimicrobial Agents and Chemotherapy.

Untargeted metabolomics analysis reveals key pathways responsible for the synergistic killing of colistin and doripenem combination against Acinetobacter baumannii

Brian T. Tsuji, J. Li, R. Nation, 2017, Scientific Reports.

Using machine learning to optimise antibiotic combinations: dosing strategies for meropenem and polymyxin B against carbapenem-resistant Acinetobacter baumannii.

C. Landersdorfer, R. Nation, Jian Li, 2020, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus.

Brian T. Tsuji, O. Cars, V. Tam, 2015, The Lancet. Infectious diseases.

Attenuation of Colistin Bactericidal Activity by High Inoculum of Pseudomonas aeruginosa Characterized by a New Mechanism-Based Population Pharmacodynamic Model

Neang S. Ly, Brian T. Tsuji, W. Jusko, 2010, Antimicrobial Agents and Chemotherapy.

New Polymyxin B Dosing Strategies To Fortify Old Allies in the War against KPC-2-Producing Klebsiella pneumoniae

B. Shin, J. Li, R. Nation, 2017, Antimicrobial Agents and Chemotherapy.

High-Dose Ampicillin-Sulbactam Combinations Combat Polymyxin-Resistant Acinetobacter baumannii in a Hollow-Fiber Infection Model

Brian T. Tsuji, B. Shin, R. Nation, 2017, Antimicrobial Agents and Chemotherapy.

Research priorities towards precision antibiotic therapy to improve patient care.

C. Landersdorfer, Jian Li, S. Wicha, 2022, The Lancet. Microbe.

Colistin and Polymyxin B Dosage Regimens against Acinetobacter baumannii: Differences in Activity and the Emergence of Resistance

Brian T. Tsuji, J. Li, R. Nation, 2016, Antimicrobial Agents and Chemotherapy.

Polymyxin Resistance in Acinetobacter baumannii: Genetic Mutations and Transcriptomic Changes in Response to Clinically Relevant Dosage Regimens

Brian T. Tsuji, Matthew D. Johnson, J. Boyce, 2016, Scientific Reports.

Quantifying Subpopulation Synergy for Antibiotic Combinations via Mechanism-Based Modeling and a Sequential Dosing Design

Neang S. Ly, C. Landersdorfer, J. Bulitta, 2013, Antimicrobial Agents and Chemotherapy.

Combating Multidrug‐Resistant Bacteria by Integrating a Novel Target Site Penetration and Receptor Binding Assay Platform Into Translational Modeling

Brian T. Tsuji, Nirav R. Shah, R. Bonomo, 2021, Clinical pharmacology and therapeutics.

Four Decades of β-Lactam Antibiotic Pharmacokinetics in Cystic Fibrosis

A. Oliver, C. Landersdorfer, G. Drusano, 2018, Clinical Pharmacokinetics.

Evaluation of the pharmacokinetics-pharmacodynamics of fusidic acid against Staphylococcus aureus and Streptococcus pyogenes using in vitro infection models: implications for dose selection.

S. Bhavnani, P. Ambrose, A. Forrest, 2011, Diagnostic microbiology and infectious disease.

Vancomycin and Daptomycin Pharmacodynamics Differ against a Site-Directed Staphylococcus epidermidis Mutant Displaying the Small-Colony-Variant Phenotype

B. Tsuji, C. von Eiff, M. Wu, 2009, Antimicrobial Agents and Chemotherapy.

Optimizing use of quinolones in the critically ill.

A. Forrest, B. Tsuji, Jenny C. Yang, 2007, Seminars in respiratory and critical care medicine.

Polymyxin Combinations Combat Escherichia coli Harboring mcr-1 and blaNDM-5: Preparation for a Postantibiotic Era

Brian T. Tsuji, J. Li, R. Nation, 2017, mBio.

In vitro pharmacodynamic evaluation of ceftolozane/tazobactam against β-lactamase-producing Escherichia coli in a hollow-fibre infection model.

R. Soon, A. Forrest, B. Tsuji, 2017, International journal of antimicrobial agents.

Determining the optimal dosing of a novel combination regimen of ceftazidime/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model.

V. Fowler, R. Bonomo, A. Eakin, 2020, The Journal of antimicrobial chemotherapy.

Attenuated Vancomycin Bactericidal Activity against Staphylococcus aureus hemB Mutants Expressing the Small-Colony-Variant Phenotype

Patrick F. Smith, A. Forrest, B. Tsuji, 2008, Antimicrobial Agents and Chemotherapy.

Decreased Vancomycin Susceptibility in Staphylococcus aureus Caused by IS256 Tempering of WalKR Expression

Kenneth D. Doig, T. Seemann, K. Doig, 2013, Antimicrobial Agents and Chemotherapy.

Decreased Vancomycin Susceptibility in Staphylococcus aureus caused by IS 256 Tempering of 1 WalKR Expression 2 3

Brian T. Tsuji, Kenneth D. Doig, T. Seemann, 2013 .

Correlation of vancomycin and daptomycin susceptibility in Staphylococcus aureus in reference to accessory gene regulator (agr) polymorphism and function.

G. Kaatz, M. Rybak, W. Rose, 2007, The Journal of antimicrobial chemotherapy.

Pharmacodynamics of dose-escalated ‘front-loading’ polymyxin B regimens against polymyxin-resistant mcr-1-harbouring Escherichia coli

R. Nation, Jian Li, Gerard D. Wright, 2017, The Journal of antimicrobial chemotherapy.

Vancomycin Bactericidal Activity as a Predictor of 30-Day Mortality in Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia

H. Ishikura, A. Matsunaga, B. Tsuji, 2011, Antimicrobial Agents and Chemotherapy.

Presence of both heterogeneous vancomycin-intermediate resistance and β-lactam antibiotic-induced vancomycin resistance phenotypes is associated with the outcome in methicillin-resistant Staphylococcus aureus bloodstream infection

T. Ishikawa, H. Ishikura, A. Matsunaga, 2013, Scandinavian journal of infectious diseases.

The Utility of Acute Physiology and Chronic Health Evaluation II Scores for Prediction of Mortality among Intensive Care Unit (ICU) and Non-ICU Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia

Brian T. Tsuji, V. Stevens, A. Forrest, 2012, Infection Control & Hospital Epidemiology.

Pharmacokinetics of four different brands of colistimethate and formed colistin in rats.

Brian T. Tsuji, J. Li, R. Nation, 2013, The Journal of antimicrobial chemotherapy.

Consistent global approach on reporting of colistin doses to promote safe and effective use.

Brian T. Tsuji, O. Cars, V. Tam, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Evaluation of daptomycin, telavancin, teicoplanin, and vancomycin activity in the presence of albumin or serum.

Brian T. Tsuji, Ronald N. Jones, P. Rhomberg, 2008, Diagnostic microbiology and infectious disease.

Predictors of agr Dysfunction in Methicillin-Resistant Staphylococcus aureus (MRSA) Isolates among Patients with MRSA Bloodstream Infections

Brian T. Tsuji, D. Hardy, A. Forrest, 2011, Antimicrobial Agents and Chemotherapy.

Application of pharmacokinetic-pharmacodynamic modeling and the justification of a novel fusidic acid dosing regimen: raising Lazarus from the dead.

Brian T. Tsuji, S. Bhavnani, P. Ambrose, 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Daptomycin pharmacodynamics against Staphylococcus aureus hemB mutants displaying the small colony variant phenotype.

B. Tsuji, C. von Eiff, D. Begic, 2009, The Journal of antimicrobial chemotherapy.

Pharmacokinetic/pharmacodynamic evaluation of the efficacy and safety of daptomycin against Staphylococcus aureus.

Brian T. Tsuji, R. Soon, A. Forrest, 2013, International journal of antimicrobial agents.

Pharmacodynamics of cefprozil against Haemophilus influenzae in an in vitro pharmacodynamic model.

Ronald N. Jones, Patrick F. Smith, S. Bhavnani, 2006, Diagnostic microbiology and infectious disease.

Pharmacology Pharmacodynamics of cefprozil against Haemophilus influenzae in an in vitro pharmacodynamic model B

Ronald N. Jones, Patrick F. Smith, S. Bhavnani, 2006 .

Native valve Proteus mirabilis endocarditis: successful treatment of a rare entity formulated by in vitro synergy antibiotic testing

K. Mergenhagen, B. Tsuji, C. Berenson, 2016, BMJ Case Reports.

Pharmacokinetics/pharmacodynamics of systemically administered polymyxin B against Klebsiella pneumoniae in mouse thigh and lung infection models

Brian T. Tsuji, J. Li, C. Landersdorfer, 2018, The Journal of antimicrobial chemotherapy.

Pharmacodynamic Variability beyond That Explained by MICs

Neang S. Ly, R. Soon, A. Forrest, 2013, Antimicrobial Agents and Chemotherapy.

Mechanistic Insights to Combating NDM- and CTX-M-Coproducing Klebsiella pneumoniae by Targeting Cell Wall Synthesis and Outer Membrane Integrity

Liang Chen, J. Bulitta, B. Tsuji, 2022, Antimicrobial agents and chemotherapy.

Azithromycin Pharmacodynamics against Persistent Haemophilus influenzae in Chronic Obstructive Pulmonary Disease

T. Murphy, S. Sethi, B. Tsuji, 2017, Antimicrobial Agents and Chemotherapy.

Development and Qualification of a Pharmacodynamic Model for the Pronounced Inoculum Effect of Ceftazidime against Pseudomonas aeruginosa

Neang S. Ly, Brian T. Tsuji, Alan Forrest, 2008, Antimicrobial Agents and Chemotherapy.

Combatting The Rising Tide of Antimicrobial Resistance: Pharmacokinetic/Pharmacodynamic Dosing Strategies for Maximal Precision.

K. Mergenhagen, B. Tsuji, Raymond Cha, 2020, International journal of antimicrobial agents.

Translational Modeling of Antibacterial Agents

Gauri G. Rao, Neang S. Ly, Brian T. Tsuji, 2016 .

Polymyxin B and fosfomycin thwart KPC-producing Klebsiella pneumoniae in the hollow-fibre infection model.

Jian Li, R. Nation, T. Walsh, 2018, International journal of antimicrobial agents.

In vitro pharmacodynamics of novel rifamycin ABI-0043 against Staphylococcus aureus.

Brian T. Tsuji, Patrick F. Smith, A. Forrest, 2008, The Journal of antimicrobial chemotherapy.

Emergence of Polymyxin B Resistance Influences Pathogenicity in Pseudomonas aeruginosa Mutators

Neang S. Ly, J. Li, R. Nation, 2015, Antimicrobial Agents and Chemotherapy.